• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

丘脑底核刺激对患有帕金森症和LRRK2突变的患者有效。

Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations.

作者信息

Schüpbach Michael, Lohmann Ebba, Anheim Mathieu, Lesage Suzanne, Czernecki Virginie, Yaici Sadek, Worbe Yulia, Charles Perrine, Welter Marie-Laure, Pollak Pierre, Dürr Alexandra, Agid Yves, Brice Alexis

机构信息

Centre d'Investigation Clinique, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France.

出版信息

Mov Disord. 2007 Jan;22(1):119-22. doi: 10.1002/mds.21178.

DOI:10.1002/mds.21178
PMID:17080443
Abstract

Stimulation of the subthalamic nucleus (STN) improves motor signs in patients with levodopa-responsive Parkinson's disease (PD). Mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause Parkinsonism. We assessed 69 patients under STN stimulation and found heterozygous LRRK2 mutations in 9 (G2019S in 8 and T2031S in 1). The age at onset of PD, the clinical characteristics before or after neurosurgery, and the clinical response to STN stimulation were similar in both groups. Two patients with the G2019S LRRK2 mutation still benefited from STN stimulation, 9 and 10 years after surgery. Patients with LRRK2 mutations are, therefore, good candidates for STN stimulation.

摘要

刺激丘脑底核(STN)可改善左旋多巴反应性帕金森病(PD)患者的运动症状。富含亮氨酸重复激酶2(LRRK2)基因突变会导致帕金森综合征。我们评估了69例接受STN刺激的患者,发现其中9例存在LRRK2基因杂合突变(8例为G2019S突变,1例为T2031S突变)。两组患者的帕金森病发病年龄、神经外科手术前后的临床特征以及对STN刺激的临床反应相似。两名携带G2019S LRRK2突变的患者在手术后9年和10年仍从STN刺激中获益。因此,携带LRRK2基因突变的患者是STN刺激的良好候选者。

相似文献

1
Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations.丘脑底核刺激对患有帕金森症和LRRK2突变的患者有效。
Mov Disord. 2007 Jan;22(1):119-22. doi: 10.1002/mds.21178.
2
The LRRK2 G2019S mutation status does not affect the outcome of subthalamic stimulation in patients with Parkinson's disease.LRRK2 G2019S 突变状态并不影响帕金森病患者丘脑底核刺激的疗效。
Parkinsonism Relat Disord. 2013 Nov;19(11):1053-6. doi: 10.1016/j.parkreldis.2013.07.005. Epub 2013 Aug 6.
3
Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers.与非突变携带者相比,接受丘脑底核深部脑刺激的LRRK2 G2019S患者有更大改善。
BMC Neurosci. 2016 Feb 1;17:6. doi: 10.1186/s12868-016-0240-4.
4
Sustained response to deep brain stimulation in LRRK2 parkinsonism with the Y1699C mutation.LRRK2 帕金森病伴 Y1699C 突变患者的脑深部电刺激持续反应。
J Parkinsons Dis. 2012;2(4):269-71. doi: 10.3233/JPD-012121.
5
Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.帕金森病患者的运动障碍:富含亮氨酸重复激酶 2(LRRK2)G2019S 突变的影响。
Parkinsonism Relat Disord. 2012 Nov;18(9):1039-41. doi: 10.1016/j.parkreldis.2012.05.014. Epub 2012 Jun 13.
6
LRRK2 exon 41 mutations in sporadic Parkinson disease in Europeans.欧洲散发性帕金森病中LRRK2基因第41外显子突变
Arch Neurol. 2007 Mar;64(3):425-30. doi: 10.1001/archneur.64.3.425.
7
Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain.与富含亮氨酸重复激酶2(Lrrk2)相关的帕金森病是西班牙北部疾病的主要病因。
Parkinsonism Relat Disord. 2007 Dec;13(8):509-15. doi: 10.1016/j.parkreldis.2007.04.003. Epub 2007 May 30.
8
Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.在帕金森综合征和额颞叶变性的病理系列中筛查LRRK2基因G2019S突变和1441密码子突变。
J Neurol Sci. 2008 Jul 15;270(1-2):94-8. doi: 10.1016/j.jns.2008.02.010. Epub 2008 Mar 19.
9
Unilateral pallidotomy in a patient with parkinsonism and G2019S LRRK2 mutation.一名患有帕金森病和G2019S LRRK2突变患者的单侧苍白球切开术。
Mov Disord. 2009 Apr 15;24(5):791-2; author reply 792. doi: 10.1002/mds.21818.
10
Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.澳大利亚帕金森病患者中常见LRRK2突变的患病率及临床特征。
Mov Disord. 2007 May 15;22(7):982-9. doi: 10.1002/mds.21477.

引用本文的文献

1
Surgicogenomics: The Role of Genetics in Deep Brain Stimulation in Parkinson's Disease Patients.手术基因组学:遗传学在帕金森病患者深部脑刺激中的作用
Brain Sci. 2024 Aug 9;14(8):800. doi: 10.3390/brainsci14080800.
2
Motor and Non-motor Outcomes of Deep Brain Stimulation across the Genetic Panorama of Parkinson's Disease: A Multi-Scale Meta-Analysis.帕金森病遗传全景中的深部脑刺激的运动和非运动结果:多尺度荟萃分析。
Mov Disord Clin Pract. 2024 May;11(5):465-477. doi: 10.1002/mdc3.13994. Epub 2024 Feb 6.
3
Precision Medicine in Parkinson's Disease: From Genetic Risk Signals to Personalized Therapy.
帕金森病的精准医学:从遗传风险信号到个性化治疗
Brain Sci. 2022 Sep 28;12(10):1308. doi: 10.3390/brainsci12101308.
4
The Role of Genetic Data in Selecting Device-Aided Therapies in Patients With Advanced Parkinson's Disease: A Mini-Review.基因数据在晚期帕金森病患者设备辅助治疗选择中的作用:一篇综述。
Front Aging Neurosci. 2022 Jun 10;14:895430. doi: 10.3389/fnagi.2022.895430. eCollection 2022.
5
Subjective Response Measurement to Prosthesis or Device Use: Validation of the Prosthetic-Bionic Paradigm Questionnaire (PBP-Q).假体或装置使用的主观反应测量:假体仿生范式问卷(PBP-Q)的验证。
Int J Environ Res Public Health. 2022 Apr 12;19(8):4656. doi: 10.3390/ijerph19084656.
6
Clinical profiles and outcomes of deep brain stimulation in G2019S LRRK2 Parkinson disease.G2019S型亮氨酸-rich重复激酶2帕金森病患者深部脑刺激的临床特征与预后
J Neurosurg. 2021 Nov 19;137(1):184-191. doi: 10.3171/2021.7.JNS21190. Print 2022 Jul 1.
7
BDNF rs6265 Genotype Influences Outcomes of Pharmacotherapy and Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease.BDNF rs6265 基因型影响早期帕金森病药物治疗和丘脑底核深部脑刺激的疗效。
Neuromodulation. 2022 Aug;25(6):846-853. doi: 10.1111/ner.13504. Epub 2022 Jun 14.
8
Advancing Personalized Medicine in Common Forms of Parkinson's Disease through Genetics: Current Therapeutics and the Future of Individualized Management.通过遗传学推进常见帕金森病形式的个性化医学:当前疗法与个体化管理的未来
J Pers Med. 2021 Mar 1;11(3):169. doi: 10.3390/jpm11030169.
9
Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort.挪威LRRK2突变携带者中的炎症性疾病。一个队列的15年随访
Front Neurosci. 2021 Jan 28;15:634666. doi: 10.3389/fnins.2021.634666. eCollection 2021.
10
Long-Term Outcomes of Genetic Parkinson's Disease.遗传性帕金森病的长期预后
J Mov Disord. 2020 May;13(2):81-96. doi: 10.14802/jmd.19080. Epub 2020 May 29.